Biểu đồ giá cổ phiếu ANAB
ANAB Dự đoán giá cổ phiếu
AnaptysBio Inc
$69.28
-0.71%
$-0.5
Khi đóng cửa: May 05, 16:00:00 GMT-4
$69.29
0.01%
$0.01
Phiên sau giờ: May 05, 20:00:00 GMT-4
Quay lại
AnaptysBio Inc (ANAB) Dự đoán giá cổ phiếu
Thống kê chính
Giá đóng cửa trước
$69.78
Giá mở cửa
$70.93
Phạm vi ngày
$68.3 - $72.27
Phạm vi 52 tuần
$17.1 - $73.3
Khối lượng
430.7K
Khối lượng trung bình
566.0K
Tỷ suất cổ tức
--
EPS (TTM)
-0.32
Vốn hóa thị trường
$1.9B
ANAB là gì?
AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 104 full-time employees. The company went IPO on 2017-01-26. The firm manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The firm's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The firm's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).
